DIAMEDICA

DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circu... lation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.More